Biohaven slides as FDA extends review period for neuro drug

1 month ago 7

• Healthcare
• On the Move

JHVEPhoto

Shares of Biohaven (NYSE:BHVN) fell ~11% in the premarket on Thursday after the company said that the FDA has extended the review period of its marketing application for its lead drug troriluzole, targeted at spinocerebellar ataxia (SCA), a group of rare

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Biohaven slides as FDA extends review period for neuro drug